The practice of prescribing medications designed for humans to animals has grown substantially over the past decade and a half, and pharmaceutical companies have recently begun experimenting with a more direct strategy: marketing behavior-modification and “lifestyle” drugs specifically for pets.
America’s animals, it seems, have very American health problems. More than 20 percent of our dogs are overweight; Pfizer’s Slentrol was approved by the F.D.A. last year as the country’s first canine anti-obesity medication. Dogs live 13 years on average, considerably longer than they did in the past; Pfizer’s Anipryl treats cognitive dysfunction so that absent-minded pets can remember the location of the supper bowl or doggy door. For lonely dogs with separation anxiety, Eli Lilly brought to market its own drug Reconcile last year. The only difference between it and Prozac is that Reconcile is chewable and tastes like beef.
Doggy diet pills may be plainly absurd, but scientists in an expanding field known as behavioral pharmacology say that the combination of new drug therapies and progressive training techniques can solve problems that in the past almost always resulted in euthanasia. The supposed effectiveness of psychiatric medicines in treating mood and behavior issues is prompting new questions in the centuries-old debate over what, exactly, separates mankind from the beasts. If the strict Cartesian view were true — that animals are essentially flesh-and-blood automatons, lacking anything resembling human emotion, memory and consciousness — then why do animals develop mental illnesses that eerily resemble human ones and that respond to the same medications? What can behavioral pharmacology teach us about animal minds and, ultimately, our own?
Marketers have a new name for the age-old tendency to view animals as furry versions of ourselves: “humanization,” a trend that is fueling the explosive growth of the pet industry and the rise of modern pet pharma. Americans forked over $49 billion for pet products and services last year, up $11.5 billion from 2003; other than consumer electronics, pet products are the fastest-growing retail segment. The market expansion is being driven both by more pets and by more spending per pet, especially by affluent baby boomers whose children have graduated from college. A third of the total spending, and the fastest-growing category, is health care, with treatments formerly reserved for people — root canals, chemotherapy, liposuction, mood pills — being administered to pets.




There are few challenges in veterinary medicine more daunting than treating a patient for a long-term skin disorder. Chronic dermatitis cases take up about ten percent of animal hospital file folders; and these patient folders tend to be the thickest due to the multiple pages of patient history, lab test results, biopsy reports, medications and supplements dispensed, and even dermatology specialist referral summaries. Reading through all that data you would find an oft-repeated theme. Control is the goal since for sure there's no cure.
A highly complicated disease entity,
diabetes has been classified according to what pathway of energy metabolism has
been disrupted.
Does your dog cough frequently? Has he lost some weight recently? Just doesn't want to go running after that tennis ball anymore? If so, he could have heartworm disease!
Recent Comments